TipRanks on MSN3d
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...
PharmExec5d
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
Investor's Business Daily on MSN5d
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndromeManagement to host conference call and webcast today, ...
STAT6d
Soleno Therapeutics’ ‘life-changing’ rare-disease drug approved
The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...
Soleno Therapeutics announces FDA approval of VYKAT XR to treat hyperphagia
Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...
STAT5d
NIH director targets misinformation research as more turmoil rocks health agencies
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
MedCity News5d
Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug
Soleno Therapeutics drug Vykat XR has received the first FDA-approval for Prader-Willi. The regulatory decision announced late Wednesday covers the treatment of the excessive hunger, called ...
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...
PMLive5d
FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome
The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release ...
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
BioSpace5d
Soleno Wins First FDA Approval for Hyperphagia in Prader-Willi Syndrome
Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...